CYP2D6 genotype determination in the Danish population

Area of Science:

• Pharmacogenomics
• Molecular Biology
• Clinical Chemistry

Background:

• CYP2D6 enzyme activity varies significantly among individuals, impacting drug metabolism.
• Accurate CYP2D6 genotyping is crucial for predicting drug response and optimizing dosages.
• Existing genotyping methods may have limitations in sensitivity and specificity.

Purpose of the Study:

• To evaluate the accuracy of CYP2D6 genotyping using XbaI RFLP and PCR in a Danish population.
• To assess the sensitivity and specificity of the genotyping method for identifying poor metabolizers (PM).
• To correlate CYP2D6 genotype with sparteine metabolic ratio (MR) in extensive metabolizers (EM).

Main Methods:

• Genotyping of 168 healthy Danish volunteers using XbaI restriction fragment length polymorphism (RFLP) and polymerase chain reaction (PCR).
• Phenotyping by measuring sparteine metabolic ratio (MR).
• Analysis of allele frequencies for D6-wt and D6-B.

Main Results:

• Genotyping correctly identified all extensive metabolizers (EM).
• The genotyping method showed 100% specificity but only 88% sensitivity for poor metabolizers (PM), with 11 (12%) PM incorrectly genotyped as EM.
• The D6-wt allele frequency was 0.741 and D6-B was 0.194 in the Danish population.
• Median sparteine MR differed between homozygous and heterozygous D6-wt EM.

Conclusions:

• The current CYP2D6 genotyping method has high specificity but limited sensitivity for identifying poor metabolizers.
• Improvements in genotype test sensitivity for PM and predictive ability for EM are needed for greater clinical utility.
• Enhanced CYP2D6 genotyping could significantly improve therapeutic drug monitoring for drugs metabolized by this enzyme.